183 related articles for article (PubMed ID: 36463985)
21. CAMP-B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance.
Lee HW; Yip TC; Wong VW; Lim YS; Chan HL; Ahn SH; Wong GL; Choi J
Aliment Pharmacol Ther; 2024 May; 59(10):1223-1235. PubMed ID: 38425096
[TBL] [Abstract][Full Text] [Related]
22. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects.
Yuen MF; Wong DK; Sablon E; Tse E; Ng IO; Yuan HJ; Siu CW; Sander TJ; Bourne EJ; Hall JG; Condreay LD; Lai CL
Hepatology; 2004 Jun; 39(6):1694-701. PubMed ID: 15185311
[TBL] [Abstract][Full Text] [Related]
23. Systematic review of risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
Kuang XJ; Jia RR; Huo RR; Yu JJ; Wang JJ; Xiang BD; Li LQ; Peng Z; Zhong JH
J Viral Hepat; 2018 Sep; 25(9):1026-1037. PubMed ID: 29624821
[TBL] [Abstract][Full Text] [Related]
24. Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
Jang JW; Kim JS; Kim HS; Tak KY; Nam H; Sung PS; Bae SH; Choi JY; Yoon SK; Roberts LR
Clin Mol Hepatol; 2021 Jan; 27(1):207-218. PubMed ID: 33317255
[TBL] [Abstract][Full Text] [Related]
25. Nested case-control study: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance.
Gounder PP; Bulkow LR; Snowball M; Negus S; Spradling PR; Simons BC; McMahon BJ
Aliment Pharmacol Ther; 2016 Jun; 43(11):1197-207. PubMed ID: 27061300
[TBL] [Abstract][Full Text] [Related]
26. Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis.
Wong YJ; Nguyen VH; Yang HI; Li J; Le MH; Wu WJ; Han NX; Fong KY; Chen E; Wong C; Rui F; Xu X; Xue Q; Hu XY; Leow WQ; Goh GB; Cheung R; Wong G; Wong VW; Yu MW; Nguyen MH
Clin Mol Hepatol; 2023 Jul; 29(3):705-720. PubMed ID: 37157776
[TBL] [Abstract][Full Text] [Related]
27. Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: A meta-analysis.
Song A; Wang X; Lu J; Jin Y; Ma L; Hu Z; Zheng Y; Shen C; Chen X
J Viral Hepat; 2021 Apr; 28(4):601-612. PubMed ID: 33455067
[TBL] [Abstract][Full Text] [Related]
28. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Hosaka T; Sezaki H; Kobayashi M; Kumada H
Am J Med; 2006 Jan; 119(1):71.e9-16. PubMed ID: 16431195
[TBL] [Abstract][Full Text] [Related]
29. No influence of hepatic steatosis on the 3-year outcomes of patients with quiescent chronic hepatitis B.
Chang JW; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Kim SU
J Viral Hepat; 2021 Nov; 28(11):1545-1553. PubMed ID: 34382730
[TBL] [Abstract][Full Text] [Related]
30. HBsAg seroclearance in chronic hepatitis B: implications for hepatocellular carcinoma.
Kim JH; Lee YS; Lee HJ; Yoon E; Jung YK; Jong ES; Lee BJ; Seo YS; Yim HJ; Yeon JE; Park JJ; Kim JS; Bak YT; Byun KS
J Clin Gastroenterol; 2011 Jan; 45(1):64-8. PubMed ID: 20535028
[TBL] [Abstract][Full Text] [Related]
31. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma.
Liu J; Yang HI; Lee MH; Lu SN; Jen CL; Batrla-Utermann R; Wang LY; You SL; Hsiao CK; Chen PJ; Chen CJ;
Gut; 2014 Oct; 63(10):1648-57. PubMed ID: 24225939
[TBL] [Abstract][Full Text] [Related]
32. Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.
Suzuki F; Hosaka T; Suzuki Y; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
J Gastroenterol; 2019 Feb; 54(2):182-193. PubMed ID: 30136216
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analogue therapy.
Hung CH; Wang JH; Lu SN; Hu TH; Lee CM; Chen CH
J Viral Hepat; 2017 Jul; 24(7):599-607. PubMed ID: 28130815
[TBL] [Abstract][Full Text] [Related]
34. Clinical features of HBsAg seroclearance in hepatitis B virus carriers in South Korea: A retrospective longitudinal study.
Park YM; Lee SG
World J Gastroenterol; 2016 Nov; 22(44):9836-9843. PubMed ID: 27956808
[TBL] [Abstract][Full Text] [Related]
35. Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study.
Kim MA; Kim SU; Sinn DH; Jang JW; Lim YS; Ahn SH; Shim JJ; Seo YS; Baek YH; Kim SG; Kim YS; Kim JH; Choe WH; Yim HJ; Lee HW; Kwon JH; Lee SW; Jang JY; Kim HY; Park Y; Kim GA; Yang H; Lee HA; Koh M; Lee YS; Kim M; Chang Y; Kim YJ; Yoon JH; Zoulim F; Lee JH
Gut; 2020 Dec; 69(12):2214-2222. PubMed ID: 32209606
[TBL] [Abstract][Full Text] [Related]
36. Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis.
Yang HI; Tseng TC; Liu J; Lee MH; Liu CJ; Su TH; Batrla-Utermann R; Chan HL; Kao JH; Chen CJ
Clin Gastroenterol Hepatol; 2016 Mar; 14(3):461-468.e2. PubMed ID: 26598229
[TBL] [Abstract][Full Text] [Related]
37. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B.
Mak LY; Hui RW; Fung J; Liu F; Wong DK; Cheung KS; Yuen MF; Seto WK
J Hepatol; 2020 Oct; 73(4):800-806. PubMed ID: 32504663
[TBL] [Abstract][Full Text] [Related]
38. HBcrAg Predicts Hepatocellular Carcinoma Development in Chronic B Hepatitis Related Liver Cirrhosis Patients Undergoing Long-Term Effective Anti-Viral.
Chang KC; Lin MT; Wang JH; Hung CH; Chen CH; Chiu SY; Hu TH
Viruses; 2022 Nov; 14(12):. PubMed ID: 36560675
[TBL] [Abstract][Full Text] [Related]
39. Chronic hepatitis B virus infection in Asian countries.
Merican I; Guan R; Amarapuka D; Alexander MJ; Chutaputti A; Chien RN; Hasnian SS; Leung N; Lesmana L; Phiet PH; Sjalfoellah Noer HM; Sollano J; Sun HS; Xu DZ
J Gastroenterol Hepatol; 2000 Dec; 15(12):1356-61. PubMed ID: 11197043
[TBL] [Abstract][Full Text] [Related]
40. Current Knowledge of Occult Hepatitis B Infection and Clinical Implications.
Yip TC; Wong GL
Semin Liver Dis; 2019 May; 39(2):249-260. PubMed ID: 30912100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
